Helicase–primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Goodpasture EW, Teague O. Experimental production of herpetic lesions in organs and tissues of the rabbit. J. Med. Res.44,121–138 (1923).▪ Describes one of the first laboratory animal models for herpes simplex virus (HSV); the prototype for hundreds of studies that follow and the foundations for antiviral testing in animals.
  Medline CASGoogle Scholar
• 2  Cutting WC, Dreisbach RH, Halpern RM et al. Chemotherapy of virus infections. J. Immunol.57,379–390 (1947).
  Medline CASGoogle Scholar
• 3  Prusoff WH. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim. Biophys. Acta32,295–296 (1959).
  Medline CASGoogle Scholar
• 4  Field HJ, De Clercq E. Antiviral drugs: a short history of their discovery and development. Microbiol. Today31,58–61 (2004).▪ Charts the historical sequence of the major discoveries in antiviral research.
  Google Scholar
• 5  Kaufman HE, Maloney ED. IDU and cytosine arabinoside in experimental herpetic keratitis. Arch. Ophthalmol.69,626–629 (1963).
  Medline CASGoogle Scholar
• 6  Kaufman HE, Heidelberger C. Therapeutic antiviral action of 5-trifluormethyl-2´-deoxyuridine in herpes simplex keratitis. Science145,585–586 (1964).
  Medline CASGoogle Scholar
• 7  De Clercq E, Field HJ. Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. Brit. J. Pharmacol.147,1–11 (2006).
  Medline CASGoogle Scholar
• 8  Field HJ, Vere Hodge RA. Recent developments in anti-herpesvirus drugs. Brit. Med. Bul.106,213–249 (2013).
  Medline CASGoogle Scholar
• 9  Oberg B. Inhibitors of Virus-Specific Enzymes in Problems of Antiviral Therapy. Stuart-Harris CH, Oxford J (Eds). Academic Press, London, UK, 35–69 (1983).
  Google Scholar
• 10  Brockman RW, Sidwell RW, Arnett G, Shaddix S. Heterocyclic thyosemicarbazones: correlation between structure, inhibition of ribonucleotide reductase, and inhibition of DNA viruses. Proc. Soc. Exp. Biol. Med.133,609–614 (1970).
  Medline CASGoogle Scholar
• 11  Cheng YC, Nakayama K, Derse D et al.Herpes Virus Specific Enzymes: Properties, Physiological Roles and Pharmacological Implications in Herpesviruses, Clinical, Pharmacological and Basic Aspects. Shiota H, Cheng Y-C, Prusoff WH (Eds). Excerpta Medica International Congress Series, Amsterdam, The Netherlands, 47–56 (1982).
  Google Scholar
• 12  Watkins AM, Dunford PJ, Moffatt AM et al. Inhibition of virus-encoded thymidine kinase suppresses herpes simplex virus replication in vitro and in vivo.Antivir. Chem. Chemother.9,9–18 (1998).
  Medline CASGoogle Scholar
• 13  Bucknall RA, Moores H, Simms R, Hesp B. Antiviral effects of aphidicolin, a new antibiotic produced by Cephalosporium aphidocola.Antimicrob. Agents Chemother.4,294–298 (1973).
  Medline CASGoogle Scholar
• 14  Coen DM, Furman PA, Aschman DP, Schaffer PA. Mutations in the herpes simplex virus DNA polymerase gene conferring hypersensitivity to aphidicolin. Nucleic Acids Res.11,5287–5297 (1983).
  Medline CASGoogle Scholar
• 15  Helgstrand E, Eriksson B, Johansson NG et al. Trisodium phosphonoformate, a new antiviral compound. Science201,819–821 (1978).
  Medline CASGoogle Scholar
• 16  Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs48,199–226 (1994).
  Medline CASGoogle Scholar
• 17  Lischka P, Hewlett G, Wunberg T et al.In vitro and in vivo activities of the novel anticytomegalovirus compound AiC 246. Antimicrob. Agents Chemother.54,1290–1297 (2010).▪ First definitive account of letermovir, describing an exciting advance in cytomegalovirus chemotherapy.
  Medline CASGoogle Scholar
• 18  Vere Hodge A. Scientific report: highlights of the 25th ICAR 16–19 April, 2012, Sapporo, Japan. Antivir. Chem. Chemother.23,19–33, (2012).
  MedlineGoogle Scholar
• 19  Spector FC, Liang L, Giordano H, Sivaraja M, Peterson MG. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J. Virol.72,6979–6987 (1998).
  Medline CASGoogle Scholar
• 20  Field HJ, Mickleburgh I. The helicase-primase complex as a target for efective herpesvirus antivirals in DNA helicases and DNA motor proteins. In: DNA Helicases and DNA Motor Proteins. Spies M (Ed.). Springer, Berlin, Germany, 145–159 (2013).
  Google Scholar
• 21  Birkmann A, Hewlett G, Rubsamen-Schaeff H, Zimmermann H. Helicase primase inhibitors as the potential next gerneration of highly active drugs against herpes simplex viruses. Future Virol.6,1199–1209 (2011).
  CASGoogle Scholar
• 22  Biswas S, Field HJ. Helicase–Primase Inhibitors: A New Approach to Combat Herpes Simplex Virus and Varicella Zoster Virus in Antiviral Drug Strategies. De Clercq E (Ed.). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany 129–146 (2011).▪ An exhaustive chapter on helicase–primase inhibitors (HPI) and contains a detailed table of HPI-resistant mutations, a must-read in conjunction with this review.
  Google Scholar
• 23  Chono K, Katsumata K, Kontani T et al. ASP2151, a novel helicase–primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J. Antimicrob. Chemother.65,1733–1741 (2010).▪▪ First report on a multispectrum helicase–primase inhibitors with potent antiviral activities against HSV and varicella-zoster virus.
  Medline CASGoogle Scholar
• 24  Kleymann G, Fischer R, Betz UA et al. New helicase–primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med.8,392–398 (2002).▪▪ First report on N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-yl-phenyl)acetamide (AIC316 or pritelivir) as a potent HPI against HSV.
  Medline CASGoogle Scholar
• 25  Crute JJ, Grygon CA, Hargrave KD et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med.8,386–391 (2002).▪▪ A must-read paper on the BILS series of HPIs with potent in vitro and in vivo anti-HSV activities.
  Medline CASGoogle Scholar
• 26  Duan J, Liuzzi M, Paris W et al. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. Antimicrob. Agents Chemother.47,1798–1804 (2003).
  Medline CASGoogle Scholar
• 27  Liuzzi M, Kibler P, Bousquet et al. Isolation and characterization of herpes simplex virus type 1 resistant to inothiazolylphenyl-based inhibitors of the viral helicase-primase. Antiviral Res.64,161–170 (2004).
  Medline CASGoogle Scholar
• 28  Biswas S, Jennens L, Field HJ. The helicase primase inhibitor, BAY57–1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res.75,30–35 (2007).
  Medline CASGoogle Scholar
• 29  Betz UAK, Fischer R, Kleymann G, Hendrix M, Rübsamen-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY57–1293. Antimicrob. Agents Chemother.4,1766–1772 (2002).
  Google Scholar
• 30  Baumeister J, Fischer R, Eckenberg P, Henninger K, Ruebsamen-Waigmann H, Kleymann G. Superior efficacy of helicase-primase inhibitor BAY 57–1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir. Chem. Chemother.18,35–48 (2007).▪ Only paper, to date, that presents preliminary data on the potential of pritelivir in reducing establishment of HSV latency and preventing virus reactivation in guinea pig model.
  Medline CASGoogle Scholar
• 31  Sasaki S, Miyazaki D, Haruki T et al. Efficacy of herpes virus helicase-primase inhibitor, ASP2151, for treating herpes simplex keratitis in mouse model. Br. J. Ophthalmol.97,498–503 (2013).
  MedlineGoogle Scholar
• 32  Chono K, Katsumata K, Kontani T, Shiraki K, Suzuki H. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir). Biochem. Pharmacol.84,459–467 (2012).
  Medline CASGoogle Scholar
• 33  Chen Y, Bai P, Mackay S et al. Herpes simplex virus type 1 helicase-primase: DNA binding and consequent protein oligomerization and primase activation. J. Virol.85,968–978 (2011).
  Medline CASGoogle Scholar
• 34  Biswas S, Kleymann G, Swift M et al. A single drug resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target. J. Antimicrob. Chemother.61,1044–1047 (2008).▪ Describes how information on drug-resistance mutations provides vital clues to understanding differences among HPIs and general mechanism of drug action.
  Medline CASGoogle Scholar
• 35  Field HJ, Mickelburgh I, Huang M-L et al. Sensitivity of clinical isolates to helicase primase inhibitors and no detection of resistance mutations above background frequency. Presented at: 25th International Conference on Antiviral Research. Sapporo, Japan, 16–19 April 2012.
  Google Scholar
• 36  Biswas S, Jennens L, Field HJ. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57–1293 are associated with increased or decreased virus growth characteristics in tissue culture. Arch. Virol.152,1489–1500 (2007).
  Medline CASGoogle Scholar
• 37  Biswas S, Field HJ. Herpes simplex virus helicase–primase inhibitors: recent findings from the study of drug resistance mutations. Antivir. Chem. Chemother.19,1–6 (2008).
  Medline CASGoogle Scholar
• 38  Field HJ, Biswas S. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus. Drug Resist. Update14,45–51 (2011).
  Medline CASGoogle Scholar
• 39  Zhu L, Weller SK. The six conserved helicase motifs of the UL5 gene product, a component of the herpes simplex virus type 1 helicase-primase, are essential for its function. J. Virol.66,469–479 (1992).
  Medline CASGoogle Scholar
• 40  Biswas S, Tiley LS, Zimmermann H, Birkmann A, Field HJ. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase–primase inhibitors, variously affect virus growth rate and pathogenicity. Antiviral Res.80,81–85 (2008).
  Medline CASGoogle Scholar
• 41  Biswas S, Miguel RN, Sukla S, Field HJ. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure. J. Gen. Virol.90,1937–1942 (2009).
  Medline CASGoogle Scholar
• 42  Biswas S, Swift M, Field HJ. High frequency of spontaneous helicase–primase inhibitor (BAY 57–1293) drug-resistant variants in certain laboratory isolates of HSV-1. Antivir. Chem. Chemother.18,13–23 (2007).
  Medline CASGoogle Scholar
• 43  Biswas S, Smith C, Field HJ. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57–1293 at high frequency in two of ten recent clinical isolates of HSV-1. J. Antimicrob. Chemother.60,274–279 (2007).
  Medline CASGoogle Scholar
• 44  Sukla S, Biswas S, Birkmann A, Lischka P, Zimmermann H, Field H. Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor. J. Antimicrob. Chemother.65,1347–1352 (2010).▪ Evidence that certain HPI-resistance mutations pre-exist at high frequency in parental virus populations and were not induced by pritelivir.
  Medline CASGoogle Scholar
• 45  Biswas S, Sukla S, Paulsen D et al. Efficacious treatment of a helicase-primase inhibitor resistant herpes simplex virus-1 mutant with AIC316 in a murine infection model. Presented at: 36th Annual International Herpesvirus Workshop. Gdansk, Poland, 24–28 July 2011.
  Google Scholar
• 46  Sukla S, Biswas S, Birkmann A et al. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant. Antiviral Res.87,67–73 (2010).
  Medline CASGoogle Scholar
• 47  James SH, Kimberlin DW, Whitley RJ. Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. Antiviral Res.83,207–213 (2009).
  Medline CASGoogle Scholar
• 48  Spruance SL, Bodsworth N, Resnick H et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J. Am. Acad. Dermatol.55,47–53 (2006).
  MedlineGoogle Scholar
• 49  Harmenberg J, Oberg B, Spruance S. Prevention of ulcerative lesions by episodic treatment or recurrent herpes labialis: a literature review. Acta Dermato-Venereologica90,122–130 (2010).
  Medline CASGoogle Scholar
• 50  Harmenberg J. Intracellular pools of thymidine reduce the antiviral activity of acyclovir. Intervirology20,48–51 (1983).
  Medline CASGoogle Scholar
• 51  Field HJ, Huang M-L, Lay EM, Mickleburgh I, Zimmermann H, Birkmann A. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase–primase inhibitor pritelivir. Antiviral Res.100,297–299 (2013).
  Medline CASGoogle Scholar
• 52  Dodson MS, Lehman IR, Association of DNA helicase and primase activities with a subassembly of the herpes simplex virus 1 helicase-primase composed of the UL5 and UL52 gene products. Proc. Natl Acad. Sci. USA88,1105–1109 (1991).
  Medline CASGoogle Scholar
• 53  Cavanaugh, NA, Ramirez-Aguilar KA, Urban M, Kuchta RD. Herpes simplex virus-1 helicase–primase: roles of each subunit in DNA binding and phosphodiester bond formation. Biochemistry48,10199–10207 (2009).
  Medline CASGoogle Scholar
• 54  Chen Y, Carrington-Lawrence SD, Bai P, Weller SK. Mutations in the putative zinc-binding motif of UL52 demonstrate a complex interdependence between the UL5 and UL52 subunits of the human herpes simplex virus type 1 helicase/primase complex. J. Virol.79,9088–9096 (2005).
  Medline CASGoogle Scholar
• 55  Chen Y, Livingston CM, Carrington-Lawrence SD, Bai P, Weller SK. A mutation in the human herpes simplex virus type I UL52 zinc finger motif results in defective primase activity but can recruit viral polymerase and support viral replication efficiently. J. Virol.81,8742–8751 (2007).
  Medline CASGoogle Scholar
• 101  AiCuris successfully completed Phase I for novel herpes compound. www.aicuris.com/index.php/fuseaction/download/lrn_file/20091104-press-release-hsv-phase-i-e-final.pdf (Accessed 26 June 2013)
  Google Scholar
• 102  AiCuris: no resistant herpes simplex virus (HSV) observed in Phase II trial with herpes drug AIC316. www.drugs.com/clinical_trials/aicuris-no-resistant-herpes-simplex-virus-hsv-observed-phase-ii-trial-herpes-aic316-12297.html (Accessed 26 June 2013)
  Google Scholar
• 103  AiCuris surpasses 50% enrollment milestone in Phase II. Superiority trial for herpes drug pritelivir. www.aicuris.com/index.php/fuseaction/download/lrn_file/2013-01-29_pr_50percent-recruitment-aic316-press-release.pdf (Accessed 26 June 2013)
  Google Scholar
• 104  Clinical trials. http://clinicaltrials.gov/ct2/show/NCT01658826?term=aic316&rank=1 (Accessed 26 June 2013)
  Google Scholar